Drugs Encyclopedia |
||
| Drugs Encyclopedia -> Weight Loss -> Acomplia | ||
| DRUG INFO: | ||
|---|---|---|
|
Appetite Suppressants: Generic name: - Phentermine Brand name: - Adipex-P - Fastin - Ionamin Generic name: - Phendimetrazine Brand name: - Bontril - Plegine - Prelu-2 Generic name: - Diethylpropion Brand name: - Tenuate - Tenuate dospan Generic name: - Rimonabant Brand name: - Acomplia - Zimulti Lipase Inhibitors (Fat Blocker): Generic name: - Orlistat Brand name: - Xenical |
|
|
Zimulti and Acomplia are brand names by Sanofi for Rimonabant: Acomplia is a
brand name for Rimonabant in the UK and rest of Europe and Zimulti is a
contemplated name for Rimonabant, intended for its launch in the US. It has not
yet been made saleable in the US market (31-May-2007), but Acomplia was made
saleable in Europe after an agreement made by the 25-member European Union in
June 2006.
Acomplia is an anorectic diet pill indicated for the treatment of obesity.
Acomplia works by blocking endogenous cannabinoid binding to neuronal CB1
receptors. Activation of these receptors by endoegenous cannabinoids, such as
anadamide, increases appetite.
Acomplia is a selective CB1 endocannabinoid receptor antagonist. It acts by
obstructing these receptors. Thus resulting in reduced appetite.
It is the most advanced endocannabinoid receptor antagonist in clinical
development and offers a novel therapeutic approach to appetite control and
weight reduction.